FLETCHER PEAVY: Open Payments
NPI 1437869526 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,473 in 67 payments from 16 companies in 2025. Trend: 2023 $1,183 · 2024 $1,843 · 2025 $1,473
Food & beverage: $1,389Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 16 | $255 |
| Gilead Sciences, Inc. | 10 | $240 |
| Celltrion USA Inc. | 8 | $165 |
| Janssen Scientific Affairs, LLC | 1 | $138 |
| GENZYME CORPORATION | 7 | $113 |
| Ipsen Biopharmaceuticals, Inc | 5 | $109 |
| ABBVIE INC. | 4 | $102 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $94 |
| Intra-Sana Laboratories | 1 | $50 |
| Intercept Pharmaceuticals, Inc. | 2 | $47 |
Products named: TREMFYA, VEGZELMA, DUPIXENT, IQIRVO, XIFAXAN, SKYRIZI, RELTONE 200 MG, OCALIVA.
Industry payments across NV — which companies pay providers there.
